Passage Bio to Report Third Quarter 2021 Financial Results on November 4, 2021
Passage Bio (NASDAQ: PASG) will host a conference call on November 4, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results and recent business highlights. Investors can join by calling 833-528-0605 (domestic) or 830-221-9711 (international) using conference ID 2985094, or watch a live webcast on the company's website. The event will be archived for 30 days post-event. The company focuses on gene therapies for central nervous system disorders and collaborates with the University of Pennsylvania's Gene Therapy Program to advance its pipeline.
- Collaboration with the University of Pennsylvania enhances access to gene therapy innovations.
- Focus on developing transformative therapies for central nervous system disorders.
- None.
PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 4, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.
To access the live conference call, please dial 833-528-0605 (domestic) or 830-221-9711 (international) and refer to conference ID 2985094. A live audio webcast of the event will be available on the Investors & News section of Passage Bio’s website at investors.passagebio.com. The archived webcast will be available on Passage Bio's website approximately two hours after the completion of the event and for 30 days following the call.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming genetic medicines for patients with CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Passage Bio Investors:
Stuart Henderson
Passage Bio
267-866-0114
shenderson@passagebio.com
Passage Bio Media:
Gwen Fisher
Passage Bio
215-407-1548
gfisher@passagebio.com
FAQ
When will Passage Bio report its third quarter 2021 financial results?
How can I access Passage Bio's conference call?
Is there a webcast available for Passage Bio's financial results call?
What is the focus of Passage Bio's business?
